Endo Pharmaceuticals
Endo Pharmaceuticals began as a family-owned business in 1920 in New York City. In 1969, it was acquired by the DuPont Company, which formed a joint venture with Merck & Co. in 1990. A new era in Endo’s history began in 1997, when Endo was formed as an independent company through a management buyout from DuPont Merck.
At A Glance
Address
100 Endo Boulevard
Chadds Ford, PA 19317
Phone: (610) 558-9800
Fax: (484) 840-4217
www.endo.com
Products
Branded and generic pain management products.
Employees
1,200
Chairman of the Board
Roger H. Kimmel
President and Chief Executive Officer
David P. Holveck
Executive Vice President Research & Development
Ivan Gergel, MD
|
“Today, Endo is a fully integrated specialty pharmaceutical company with market leadership in pain management,” said Blaine Davis, Vice President of Investor Relations & Communications. “Our goal is to expand into complementary therapeutic areas such as neurology and supportive care oncology.”
He noted that net sales for 2007 were $1.09 billion.
Flagship Products
Endo’s top-selling product is Lidoderm® (lidocaine patch 5%), a branded topical skin patch that was the first topical treatment approved by the FDA to help relieve the pain of post-herpetic neuralgia, also referred to as post-shingles pain. Net sales of Lidoderm® were $705.5 million in 2007.
Other Products
- Voltaren® Gel (diclofenac sodium topical gel) 1% is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the hands and knees.
- Opana ER® (oxymorphone HCl) tablets CII, an extended-release oral form of oxymorphone that has been studied in a wide range of chronic pain conditions, including osteoarthritis, cancer pain and low back pain. Opana ER® is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time and is not intended to be used on an as-needed basis.
- Opana® (oxymorphone HCl) tablets CII, an immediate-release formulation of oxymorphone, is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate.
- Percocet® (oxycodone and acetaminophen tablets, USP) is indicated for the relief of moderate to moderately severe pain.
- Frova® (frovatriptan) is indicated for the treatment of acute migraine headaches in adults.
- Endo also markets selected generic products including Endocet® and morphine sulfate ER.
In the Pipeline
Endo’s pipeline portfolio is composed primarily of products intended to address acute, chronic and neuropathic pain conditions and related therapeutic areas such as neurology and supportive care oncology.
The company’s sales force calls on specialty pain physicians and community-based physicians.
This corporate profile was reviewed and approved by Endo Pharmaceuticals.
Close
|
